Skip to main content

Kymera Therapeutics, Inc.

KYMR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001815442

In the last 90 days, Kymera Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 300 institutions reported holding it in 13F filings for Q3 2026, worth $11.1B in total; no superinvestor holds it.

Key figures

Market capClose on Nov 18, 2026
$10.3B
Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $4.16M in total
2
13F holdersQ3 2026, +26 vs. previous quarter
300
13F valueReported value at the end of Q3 2026
$11.1B
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$39.2M
−16.7% year over year
Net income, FY2025
-$311.4M
No comparable prior period
Free cash flow, FY2025
-$234.3M
No comparable prior period
Revenue, Q3 FY2026
$0
−100.0% year over year

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
8.40M
Shares sold short
Change
−770.6K
−8.4% vs. previous
Days to cover
10.49
At average daily volume

Superinvestors holding KYMR, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding KYMR at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Kymera Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Oct 1, 2026 (view filing)5:20 PM ETOct 1Same dayMainolfi NelloChief Executive OfficerSSale−30.0K$113.80−$3.41M−4.3%666.6K after6 lots10b5-1
Sep 4, 2026 (view filing)6:00 PM ETSep 4Same dayAdams BrianChief Legal OfficerSSale−6.37K$116.83−$744.3K−11.3%50.3K after3 lots
Jul 7, 2026 (view filing)8:00 PM ETJul 7Same dayMainolfi NelloChief Executive OfficerSSale−50.0K$119.00−$5.95M−7.0%666.6K after10b5-1
Jul 2, 2026 (view filing)6:30 PM ETJun 302 daysJacobs Bruce N.Chief Financial OfficerSSale−77.1K$114.96−$8.86M−23.9%244.9K after8 lots10b5-1
Jul 2, 2026 (view filing)6:30 PM ETJul 11 dayGoodman NoahChief Business OfficerSSale−3.39K$114.29−$387.3K−6.7%47.2K after10b5-1
Jul 2, 2026 (view filing)6:30 PM ETJul 11 dayMainolfi NelloChief Executive OfficerSSale−80.0K$115.29−$9.22M−10.7%666.6K after5 lots10b5-1
Jul 2, 2026 (view filing)5:39 PM ETJun 293 daysBooth BruceDirectorSSale−76.7K$108.05−$8.28M−14.2%462.9K afterAmended14 lots10b5-1
Jun 30, 2026 (view filing)Jun 291 dayBooth BruceDirectorSSale−31.3K$109.48−$3.42M−6.3%461.8K after8 lots10b5-1
Jun 30, 2026 (view filing)Jun 26-294 daysBooth BruceDirectorSSale−513.2K$110.01−$56.5M−52.4%466.1K after30 lots10b5-1
Jun 26, 2026 (view filing)6:48 PM ETJun 26Same dayBiotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and FootnotesSSaleCommon Stock, $0.0001 par value−1.58M$106.50−$168.1M−86.8%240.1K after3 lots

Top 10 13F holders, Q3 2026

See all 300 holders

The largest institutional positions in Kymera Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding KYMR in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
FMR LLC12,568,921$1.41B0.06%+219,665+1.8%Added
Price T Rowe Associates Inc8,725,908$975.5M0.10%+1,612,928+22.7%Added
Baker Bros. Advisors LP8,657,242$967.8M4.60%00.0%Unchanged
Avoro Capital Advisors LLC7,474,747$835.6M8.62%00.0%Unchanged
BlackRock, Inc.5,825,416$651.2M0.01%+287,206+5.2%Added
T. Rowe Price Investment Management, Inc.5,736,316$641.3M0.45%−520,945−8.3%Reduced
BVF Inc3,872,052$432.9M14.24%00.0%Unchanged
Wellington Management Group LLP3,706,994$414.4M0.07%+31,966+0.9%Added
Vanguard Capital Management LLC3,044,214$340.3M0.01%+111,836+3.8%Added
Vanguard Portfolio Management LLC2,978,521$333.0M0.02%−13,672−0.5%Reduced

Holders of 5% or more of KYMR

See all 6 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Kymera Therapeutics, Inc..

Largest holders of KYMR from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
FMR LLC13G/A14.30%11.7M shares+3.10 ppfrom 11.20%Feb 8, 20217 filingsMay 6, 2026SEC
Baker Bros. Advisors LP13D/A10.90%8.68M shares+1.40 ppfrom 9.50%Feb 14, 20236 filingsDec 11, 2025SEC
Price T Rowe Associates Inc13G/A10.70%8.87M shares+2.10 ppfrom 8.60%Feb 14, 20229 filingsSep 8, 2026SEC
T. Rowe Price Investment Management, Inc.13G6.70%5.46M sharesNewMay 15, 20261 filingMay 15, 2026SEC
BlackRock, Inc.13G/A6.60%5.45M shares+1.20 ppfrom 5.40%Jul 17, 20252 filingsOct 27, 2026SEC